Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × Paclitaxel × Clear all

Phase

Phase 2 29 Phase 3 10 Phase 1/2 4 Phase 1 4 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 8 Ovarian Neoplasms 6 Fallopian Tube Neoplasms 5 Lung Neoplasms 4 Stomach Neoplasms 3 Esophageal Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Inflammatory Breast Neoplasms 2 Head and Neck Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Ductal, Breast 2 Adenocarcinoma Of Esophagus 2 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 The Neoadjuvant Therapy 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Teratoma 1 Stage IIIB or IV Non-Small Cell Lung Cancer 1 Seminoma 1 Recurrence 1 Primary Malignant Neoplasm of Ovary 1 Peripheral Nervous System Diseases 1 Pancreatic Neoplasms 1 Neoplasms, Cystic, Mucinous, and Serous 1 Neoplasm Metastasis 1

Interventions

Temozolomide 3 Gemcitabine 3 Etoposide 3 pembrolizumab 2 Rituximab 2 Lomustine 2 Haloperidol 2 Dexamethasone 2 Cyclosporine 2 vocimagene amiretrorepvec 1 trofosfamide 1 tinostamustine 1 selinexor 1 ruxolitinib 1 regorafenib 1 peginterferon alfa-2b 1 osimertinib 1 menatetrenone 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 imetelstat 1 glumetinib 1 fludarabine 1 etoposide phosphate 1 eculizumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carbon-11 acetate 1 blinatumomab 1 auricularum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03315364 2026-04-01

OPTIMAL

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡